DSNKY (Daiichinkyo Co) Debt-to-Asset : 0.03 (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Debt-to-Asset?

Daiichinkyo Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3 Mil. Daiichinkyo Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $707 Mil. Daiichinkyo Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $23,064 Mil. Daiichinkyo Co's debt to asset for the quarter that ended in Sep. 2024 was 0.03.

Daiichinkyo Co Debt-to-Asset Historical Data

The historical data trend for Daiichinkyo Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Debt-to-Asset Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.11

0.09

0.07

0.06

0.03

Daiichinkyo Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.04	0.04	0.03	-	0.03

Competitive Comparison of Daiichinkyo Co's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Debt-to-Asset falls into.

Daiichinkyo Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Daiichinkyo Co's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.663	+	676.244)	/	23102.172
	=	0.03

Daiichinkyo Co's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.798	+	707.381)	/	23064.265
	=	0.03

Daiichinkyo Co (OTCPK:DSNKY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Daiichinkyo Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DSKYF:USA 4568:Mexico 4568:Japan D4S:Germany D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.